Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study will enroll up to 40 participants.
- 20 participants at Stanford injected with an FDA-approved PET tracer (e.g. amyloid, FDG, etc.), and
- 20 participants from Stanford who have been pre-injected with a radiopharmaceutical for a study on another PET imaging system
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Paul Newswanger
- Phone Number: (650) 736-1349
- Email: pdn@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford University
-
Contact:
- Paul Newswanger, MPH
- Phone Number: 650-736-1349
- Email: pdn@stanford.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Whole body radiation dose within the last year of less than 5000 mrem
- Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved
- Subjects will be at least 21 years of age
- Subject provides written informed consent
- Subject is deemed healthy by the PI by via self-reported questionnaire
Exclusion Criteria:
- For patients who will be receiving a tracer injection, no known allergy to the imaging agents
- Participant has a history of or current diagnosis of cancer
- Participant is pregnant or nursing
- Metallic implants (contraindicated for MRI)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm-1
20 participants will be recruited, inject with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
|
|
|
Experimental: Arm-2
20 participants will be recruited from other imaging studies that have been already injected (pre-injected) with a radiopharmaceutical.
These subjects wont receive an additional injection of radiopharmaceutical.
|
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PETMR image
Time Frame: Up to 24 months
|
The key specific measurement is the resulting PET/MR image obtained from the single subject scan.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-55044
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.